
11 - 50 employees
Founded 2017
🧬 Biotechnology
💊 Pharmaceuticals
⚕️ Healthcare Insurance
Biotechnology • Pharmaceuticals • Healthcare Insurance
Akero Therapeutics is a company pioneering novel therapies to transform the lives of people living with serious metabolic diseases. Their flagship program, Efruxifermin (EFX), is aimed at treating metabolic dysfunction-associated steatohepatitis (MASH) and is currently undergoing multiple clinical trials. Akero is committed to advancing medicine in the field of metabolic diseases and has a strong focus on research, development, and clinical studies.
🕒 April 1
Principal Scientist supporting analytical development and characterization for late-stage biologic development at Akero Therapeutics. Collaborating with cross-functional teams and engaging in regulatory submissions.
🕒 April 1
Associate Director leading late-stage drug product development for metabolic disease therapies at Akero Therapeutics. Collaborating with internal and external partners to optimize manufacturing processes and regulatory submissions.
🕒 January 28
Director/Sr. Director of Clinical Development at Akero Therapeutics focusing on Phase 3 clinical trials execution. Collaborating with teams as Medical Monitor and contributing to regulatory submissions.